Complete Monograph method for Aripiprazole according to USP

08/10/2015

Aripiprazole is an atypical antipsychotic, and it is a partial dopamine agonist.
It is primarily used in the treatment of schizophrenia, bipolar disorder, major depressive disorder, tic disorders, and irritability associated with autism. Common commercial brand names: Abilifyand Aripiprex.

Aripiprazole was first approved by the U.S. Food and Drug Administration (FDA) for schizophrenia in November 2002 and the European Medicines Agency in June 2004; for acute manic and mixed episodes associated with bipolar disorder.

Log in or register to read this article in full and gain access to The Analytical Scientist’s entire content archive. It’s FREE!

Email*

Choose a password

I have read and understand the Privacy Notice *

Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

Receive communication from The Cannabis Scientist I want to stay up to date with the Mass Spectrometry field I want to stay up to date with the Spectroscopy field

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.